Trial Profile
A Sequential Phase I Study of MEK1/2 Inhibitors PD-0325901 or Binimetinib Combined With cMET Inhibitor PF-02341066 in Patients With RAS Mutant and RAS Wild Type (With Aberrant c-MET) Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Crizotinib (Primary) ; Mirdametinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms MErCuRIC1
- 01 Oct 2019 Status changed from active, no longer recruiting to completed.
- 28 Mar 2019 This trial has been completed in Ireland (2018-12-03) according to European Clinical Trials Database record.
- 28 Mar 2019 This trial has been completed in Belgium (2018-12-03) according to European Clinical Trials Database record.